A Northwestern University team described heterobifunctional proteomimetic polymers (HYDRACs) that bind disordered oncogenic proteins like MYC and KRAS and recruit cellular degradation machinery, achieving selective target destruction in cell lines and tumor models. The polymeric approach displays multiple binding motifs and degrons on a single backbone, enabling engagement without requiring classical ligandable pockets. In vitro and in vivo data showed tumor accumulation, reduction in oncogenic signaling, and tumor growth inhibition, positioning polymer‑based degraders as a complementary modality to small molecules and PROTACs. The architecture aims to overcome limitations of traditional binders for intrinsically disordered proteins. If translatable, proteomimetic polymers could expand the degradable proteome and provide new therapeutic avenues for cancers driven by historically intractable oncoproteins.